Indication

For the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.

Medicine details

Medicine name:
caplacizumab (Cablivi)
SMC ID:
SMC2266
Pharmaceutical company
Sanofi
BNF chapter
Nutrition and blood
Submission type
Full
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
TBC